rifaximin is effective for the treatment of clostridium difficile—associated diarrhea results of an open-label pilot studyrifaximin是有效治疗难治性梭状芽孢杆菌相关腹泻的非盲试验研究的结果.pdfVIP

Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2011, Article ID 106978, 5 pages doi:10.1155/2011/106978 Clinical Study Rifaximin Is Effective for the Treatment of Clostridium difficile—Associated Diarrhea: Results of an Open-Label Pilot Study David T. Rubin,1, 2 Sunana Sohi,1 Matthew Glathar,1 Tojo Thomas,1 Nicole Yadron,1 and Bonnie L. Surma1 1 University of Chicago Medical Center, Chicago, IL 60637, USA 2 Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medical Center, Chicago, IL 60637, USA Correspondence should be addressed to David T. Rubin, drubin@ Received 11 February 2011; Revised 15 September 2011; Accepted 20 September 2011 Academic Editor: Genevieve B. Melton-Meaux Copyright © 2011 David T. Rubin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objectives. This open-label trial assessed the efficacy and safety of rifaximin as first-line therapy in hospitalized patients with Clostridium diffi cile-associated diarrhea (CDAD). Methods. We enrolled thirteen patients who had a confirmed diagnosis of CDAD characterized by ≥3 unformed stools/day and positive C. diffi cile toxin assay. Those patients received rifaximin 400 mg three times daily for 10 days. Resolution of symptoms, repeat assay 10 days after treatment, and followup for recurrence were assessed. Results. Eight patients completed the study, and all reported symptom resolution during treatment. Mean time to last unformed stool was 132 h ± 42.5 h. Seven patients had no relapse by week 2 and in longer followup (median 162 days). One patient had recurrent CDAD during a repeat hospitalizati